Literature DB >> 12806617

Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells.

Quan Liao1, Junchao Guo, Jörg Kleeff, Arthur Zimmermann, Markus W Büchler, Murray Korc, Helmut Friess.   

Abstract

BACKGROUND & AIMS: In both pancreatic cancer and chronic pancreatitis, there is enhanced expression of mitogenic growth factors and their tyrosine kinase receptors, which have the capacity to activate mitogen-activated protein kinase (MAPK). In view of the important role of MAPK kinase phosphatase (MKP)-1 in the regulation of MAPK activation, the expression and functional role of MKP-1 was analyzed.
METHODS: Pancreatic tissues were analyzed by Northern blotting, Western blotting, and immunohistochemistry. Pancreatic cancer cells were transfected with a full-length MKP-1 antisense construct. Growth characteristics and tumorigenicity in vivo and the effects of mitogenic growth factors on cell growth and MAPK activation were determined in transfected and control cells.
RESULTS: MKP-1 messenger RNA (mRNA) levels were increased in pancreatic cancer and chronic pancreatitis (CP) tissues. Moderate to strong MKP-1 immunoreactivity was present in the cancer cells, ductal cells of pancreatic intraepithelial neoplasia, and in tubular complexes in CP. Down-regulation of MKP-1 resulted in decreased anchorage-dependent and -independent growth of pancreatic cancer cells, and decreased tumorigenicity in a nude mouse tumor model. MKP-1 down-regulation led to decreased proliferation and sustained MAPK activation in response to mitogens.
CONCLUSIONS: Suppression of MKP-1 expression reduces the tumorigenicity of pancreatic cancer cells in vivo, suggesting that MKP-1 contributes to enhanced mitogenic signaling in pancreatic cancer cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12806617     DOI: 10.1016/s0016-5085(03)00398-6

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  33 in total

1.  Implementation of high-content assay for inhibitors of mitogen-activated protein kinase phosphatases.

Authors:  Andreas Vogt; John S Lazo
Journal:  Methods       Date:  2007-07       Impact factor: 3.608

2.  Identification of novel inhibitors of mitogen-activated protein kinase phosphatase-1 with structure-based virtual screening.

Authors:  Hwangseo Park; Jeong-Yi Jeon; Song Yi Kim; Dae Gwin Jeong; Seong Eon Ryu
Journal:  J Comput Aided Mol Des       Date:  2011-05-13       Impact factor: 3.686

3.  Tyrosine phosphatase inhibitor-3 sensitizes melanoma and colon cancer to biotherapeutics and chemotherapeutics.

Authors:  Suman Kundu; Keke Fan; Mingli Cao; Daniel J Lindner; Ralph Tuthill; Lili Liu; Stanton Gerson; Ernest Borden; Taolin Yi
Journal:  Mol Cancer Ther       Date:  2010-08-03       Impact factor: 6.261

Review 4.  Inside the human cancer tyrosine phosphatome.

Authors:  Sofi G Julien; Nadia Dubé; Serge Hardy; Michel L Tremblay
Journal:  Nat Rev Cancer       Date:  2011-01       Impact factor: 60.716

Review 5.  Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease.

Authors:  Lyn M Wancket; W Joshua Frazier; Yusen Liu
Journal:  Life Sci       Date:  2011-12-13       Impact factor: 5.037

6.  p38 MAPK in pancreatic cancer: finding a protective needle in the haystack.

Authors:  Murray Korc
Journal:  Clin Cancer Res       Date:  2014-08-18       Impact factor: 12.531

7.  Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.

Authors:  William J Irvin; Robert Z Orlowski; Wing-Keung Chiu; Lisa A Carey; Frances A Collichio; Philip S Bernard; Inge J Stijleman; Charles Perou; Anastasia Ivanova; E Claire Dees
Journal:  Clin Breast Cancer       Date:  2010-12-01       Impact factor: 3.225

8.  VHZ is a novel centrosomal phosphatase associated with cell growth and human primary cancers.

Authors:  Jing Ping Tang; Cheng Peow Tan; Jie Li; Md Monowarul Siddique; Ke Guo; Siew Wee Chan; Jung Eun Park; Wan Ngee Tay; Zhi Yuan Huang; Wen Cai Li; Jian Chen; Qi Zeng
Journal:  Mol Cancer       Date:  2010-05-28       Impact factor: 27.401

Review 9.  Regulation of innate immune response by MAP kinase phosphatase-1.

Authors:  Xianxi Wang; Yusen Liu
Journal:  Cell Signal       Date:  2007-04-20       Impact factor: 4.315

Review 10.  The role and target potential of protein tyrosine phosphatases in cancer.

Authors:  Taolin Yi; Daniel Lindner
Journal:  Curr Oncol Rep       Date:  2008-03       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.